Unique ID issued by UMIN | UMIN000010165 |
---|---|
Receipt number | R000011903 |
Scientific Title | A prospective cohort study to search for a risk factor of chemotherapy induced nausea and vomiting in patients with colorectal cancer. |
Date of disclosure of the study information | 2013/03/05 |
Last modified on | 2013/03/05 14:03:23 |
A prospective cohort study to search for a risk factor of chemotherapy induced nausea and vomiting in patients with colorectal cancer.
A prospective cohort study to search for a risk factor of chemotherapy induced nausea and vomiting in patients with colorectal cancer.
A prospective cohort study to search for a risk factor of chemotherapy induced nausea and vomiting in patients with colorectal cancer.
A prospective cohort study to search for a risk factor of chemotherapy induced nausea and vomiting in patients with colorectal cancer.
Japan |
colorectal cancer
Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Malignancy
NO
We search for a risk factor of chemotherapy induced nausea and vomiting in the colorectal cancer patient who performed standard antiemetic therapy.
Others
To search for a risk factor of chemotherapy induced nausea and vomiting in the colorectal cancer patient who performed standard antiemetic therapy.
Exploratory
Pragmatic
Phase IV
Complete response rate during 24 to 120 hours (delay phase) after an anticancer agent dosage start
1. Complete response rate during 0 to 24 hours (acute phase) and 0 to 120 hours (all phase ) after an anticancer agent dosage start
2. Complete control rate during acute phase and delay phase and all phase after an anticancer agent dosage start
3. Grade of nausea during acute phase and delay phase and all phase after an anticancer agent dosage start
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1. The patient who plans the medication of the following anticancer agents as colorectal cancer chemotherapy
CPT-11 or oxaliplatin
2. The patient whom an anticancer agent is not given to or an anticancer agent of low emetic risk has been given to in the past
3. The planned patient who gives the following antiemetic drugs in the time giving an anticancer agent
day 1 palonosetron (0.75mg) i.v.
dexamethasone (9.9mg) i.v.
day 2, 3 dexamethasone (8mg) p.o.
4. Age at the time of the registration is a patient 20 years or older
5. The patient who can fill in a diary with a symptom exactly
6. Given written informed consent
1. The patient who experienced nausea or vomiting within 24 hours before giving an anticancer agent
2. Any other inadequacy for this study
200
1st name | |
Middle name | |
Last name | Itaru Endo |
Yokohama city university graduate school of medicine
Department of gastroenterological surgery
3-9 Fukuura, Kanazawa-ku, Yokohama City, 236-0004, Japan
1st name | |
Middle name | |
Last name | Kazuki Watanabe |
Yokohama City University Hospital
Department of gastroenterological surgery
3-9 Fukuura, Kanazawa-ku, Yokohama City, 236-0004, Japan
Yokohama City University Hospital
None
Self funding
NO
横浜市立大学附属病院
横浜市立大学附属市民総合医療センター
国立病院横浜医療センター
横浜市立市民病院
藤沢市民病院
横須賀共済病院
横須賀市立市民病院
横浜市立みなと赤十字病院
済生会横浜市南部病院
済生会若草病院
横浜船員保険病院
横浜掖済会病院
長津田厚生総合病院
NTT東日本関東病院
市立伊東市民病院
2013 | Year | 03 | Month | 05 | Day |
Unpublished
Open public recruiting
2013 | Year | 02 | Month | 26 | Day |
2013 | Year | 02 | Month | 26 | Day |
prospective study
2013 | Year | 03 | Month | 05 | Day |
2013 | Year | 03 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011903